Abstract
Introduction: Refractory overactive bladder (OAB) is an all-too-familiar condition seen in clinical practice when anticholinergic medications fail or intolerable side effects prevail. Dmochowski et al. conducted a large phase 2, dose–response, double-blind, placebo-controlled, randomized trial with onabotulinumtoxinA for treatment of idiopathic OAB in 313 patients failing anticholinergic medications.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
